These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32722782)

  • 1. Treatment-associated hemolysis in Kawasaki disease: association with blood-group antibody titers in IVIG products.
    Bruggeman CW; Nagelkerke SQ; Lau W; Manlhiot C; de Haas M; van Bruggen R; McCrindle BW; Yeung RSM; Kuijpers TW
    Blood Adv; 2020 Jul; 4(14):3416-3426. PubMed ID: 32722782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease.
    Luban NL; Wong EC; Henrich Lobo R; Pary P; Duke S
    Transfusion; 2015 Jul; 55 Suppl 2():S90-4. PubMed ID: 26174904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose intravenous immunoglobulin is strongly associated with hemolytic anemia in patients with Kawasaki disease.
    Nolan BE; Wang Y; Pary PP; Luban NLC; Wong ECC; Ronis T
    Transfusion; 2018 Nov; 58(11):2564-2571. PubMed ID: 30265742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
    PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports.
    Padmore R
    Transfusion; 2015 Jul; 55 Suppl 2():S59-64. PubMed ID: 26174898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients.
    Kahwaji J; Barker E; Pepkowitz S; Klapper E; Villicana R; Peng A; Chang R; Jordan SC; Vo AA
    Clin J Am Soc Nephrol; 2009 Dec; 4(12):1993-7. PubMed ID: 19833910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemolytic anemia associated with intravenous immunoglobulin in Kawasaki disease.
    Cheon EJ; Oh JS
    BMC Pediatr; 2024 Jan; 24(1):69. PubMed ID: 38245705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of FcγRIIA and FcγRIIB on coronary artery lesion formation and intravenous immunoglobulin treatment responses in children with Kawasaki disease.
    Chang LS; Lo MH; Li SC; Yang MY; Hsieh KS; Kuo HC
    Oncotarget; 2017 Jan; 8(2):2044-2052. PubMed ID: 27893416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe Hemolytic Anemia Following Intravenous Immunoglobulin in an Infant With Kawasaki Disease.
    Tocan V; Inaba A; Kurano T; Sonoda M; Soebijanto K; Nakayama H
    J Pediatr Hematol Oncol; 2017 Mar; 39(2):e100-e102. PubMed ID: 27879540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective observational study of the incidence, natural history, and risk factors for intravenous immunoglobulin-mediated hemolysis.
    Pendergrast J; Armali C; Callum J; Cserti-Gazdewich C; Jiwajee A; Lieberman L; Lau W; Lin Y; Parmar N; Pavenski K; Riden LS; Shehata N; Willie-Ramharack K; Tomlinson G; Tong TN; Binnington B; Branch DR;
    Transfusion; 2021 Apr; 61(4):1053-1063. PubMed ID: 33433931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
    Han CL; Zhao SL
    Med Sci Monit; 2018 Oct; 24():7264-7270. PubMed ID: 30307902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
    Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
    Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
    Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
    Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V
    Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.
    Friedman KG; Gauvreau K; Hamaoka-Okamoto A; Tang A; Berry E; Tremoulet AH; Mahavadi VS; Baker A; deFerranti SD; Fulton DR; Burns JC; Newburger JW
    J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27633390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemolysis related to intravenous immunoglobulins is dependent on the presence of anti-blood group A and B antibodies and individual susceptibility.
    Mielke O; Fontana S; Goranova-Marinova V; Shebl A; Spycher MO; Wymann S; Durn BL; Lawo JP; Hubsch A; Salama A
    Transfusion; 2017 Nov; 57(11):2629-2638. PubMed ID: 28840942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF-α is superior to conventional inflammatory mediators in forecasting IVIG nonresponse and coronary arteritis in Chinese children with Kawasaki disease.
    Hu P; Jiang GM; Wu Y; Huang BY; Liu SY; Zhang DD; Xu Y; Wu YF; Xia X; Wei W; Hu B
    Clin Chim Acta; 2017 Aug; 471():76-80. PubMed ID: 28526535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemolytic anemia associated with intravenous immunoglobulin.
    Wilson JR; Bhoopalam H; Fisher M
    Muscle Nerve; 1997 Sep; 20(9):1142-5. PubMed ID: 9270670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.
    Sato S; Kawashima H; Kashiwagi Y; Hoshika A
    Int J Rheum Dis; 2013 Apr; 16(2):168-72. PubMed ID: 23773640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
    Bal AK; Prasad D; Umali Pamintuan MA; Mammen-Prasad E; Petrova A
    Pediatr Neonatol; 2014 Oct; 55(5):387-92. PubMed ID: 24636168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.